AZ reports Tagrisso's PFS benefit in NSCLC

Newly announced data from the Phase III AURA3 trial of Tagrisso osimertinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) showed that the drug improved progression-free survival (PFS) by 5.7 months vs. chemotherapy in patients with non-small cell lung cancer.

Tagrisso has accelerated approval from FDA to treat EGFR T790M mutation-positive, locally advanced or metastatic non-small cell lung cancer patients who progressed on or after an EGFR tyrosine kinase inhibitor (TKI). The drug is conditionally approved in the EU to treat NSCLC in EGFR T790M mutation-positive patients, irrespective of previous EGFR TKI treatment...